BTX - Brooklyn Immunotherapeutics (BTX) shares almost doubles; taps new CEO

Brooklyn ImmunoTherapeutics (BTX) appoints Howard J. Federoff, M.D., Ph.D., as CEO and President and a Director as of April 16, 2021.BTX shares surge 79% premarket trading at $8.38, briefly double than yesterday's close of $4.67.Dr. Federoff succeeds Ronald Guido who was serving as Interim CEO and will remain on Brooklyn’s management team as Chief Development Officer. “My top priorities will be the clinical advancement of IRX-2 in solid tumor indications as well as seeking opportunities to in-license new therapeutic agents...," said Dr. Federoff.IRX-2 has received both fast track designation and orphan drug designation from the FDA for this indication with topline results from Phase 2b trial expected in H1 of next year. Dr. Federoff is a professor of neurology at the University of California, Irvine. He is the former CEO of UCI Health, vice chancellor for health affairs and dean of the UCI School of Medicine.Dr. Federoff co-founded MedGenesis Therapeutix and Brain Neurotherapy Bio,

For further details see:

Brooklyn Immunotherapeutics (BTX) shares almost doubles; taps new CEO